[Code of Federal Regulations] [Title 21, Volume 6] [Revised as of April 1, 2004] From the U.S. Government Printing Office via GPO Access [CITE: 21CFR524.1044b] [Page 303-304] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) PART 524_OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS--Table of Contents Sec. 524.1044b Gentamicin sulfate, betamethasone valerate otic solution. (a) Specifications. Each cubic centimeter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone alcohol. (b) Sponsor. See Nos. 000061 and 051259 in Sec. 510.600(c) of this chapter. (c) Conditions of use. (1) The drug is used or indicated for use in dogs in the treatment of acute and chronic otitis externa caused by bacteria sensitive to gentamicin; the drug is also used or indicated for use in dogs and cats in the treatment of superficial infected lesions caused by bacteria sensitive to gentamicin. (2)(i) For the treatment of acute and chronic canine otitis externa caused by bacteria sensitive to gentamicin, the drug is administered by instillation of 3 to 8 drops of solution into the ear canal twice daily for 7 to 14 days. Duration of treatment will depend upon the severity of the condition and the response obtained. The duration of treatment and/ or frequency of the dosage may be reduced but care should be taken not to discontinue therapy prematurely. The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solutions. Excessive hair should be clipped from the treatment area of the external ear. (ii) For the treatment of canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin, the lesion and adjacent area should be properly cleaned before [[Page 304]] treatment. Excessive hair should be removed. A sufficient amount of the drug should be applied to cover the treatment area. The drug should be administered twice daily for 7 to 14 days. (3) If hypersensitivity to any of the components occurs treatment with this product should be discontinued and appropriate therapy instituted. Concomitant use with other drugs known to induce ototoxicity is not recommended. This preparation should not be used in conditions where corticosteroids are contraindicated. Do not administer parenteral corticosteroids during treatment with this drug. The antibiotic sensitivity of the pathogenic organism should be determined prior to use of this preparation. (4) For use by or on the order of a licensed veterinarian. [40 FR 13873, Mar. 27, 1975. Redesignated at 41 FR 14189, Apr. 2, 1976, and amended at 52 FR 7832, Mar. 13, 1987; 61 FR 48624, Sept. 16, 1996]